235 related articles for article (PubMed ID: 16518712)
1. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
Ulrich M; Berger J; Möller JG; Döring G
Infection; 2005 Dec; 33 Suppl 2():50-4. PubMed ID: 16518712
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
[TBL] [Abstract][Full Text] [Related]
6. Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae.
Kratzer C; Graninger W; Macfelda K; Buxbaum A; Georgopoulos A
Wien Klin Wochenschr; 2007; 119(9-10):297-302. PubMed ID: 17571234
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.
Ulrich M; Albers C; Möller JG; Dalhoff A; Korfmann G; Künkele F; Döring G
Antimicrob Agents Chemother; 2005 Dec; 49(12):5119-22. PubMed ID: 16304181
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of fluoroquinolones against common respiratory pathogens.
Aydemir S; Tunger A; Cilli F
West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
Piddock LJ; Jin YF
J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Elshafie SS; Al-Kuwari J
Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
[No Abstract] [Full Text] [Related]
12. Contribution of immunocompetence to the antibacterial activities of ciprofloxacin and moxifloxacin in an in vitro pharmacodynamic model.
Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():44-9. PubMed ID: 16518711
[TBL] [Abstract][Full Text] [Related]
13. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Vallet CM; Marquez B; Ngabirano E; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2011 Sep; 38(3):249-56. PubMed ID: 21764262
[TBL] [Abstract][Full Text] [Related]
14. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
15. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone.
Drago L; Mattina R; Legnani D; Romano CL; Vianello E; Ricci C; De Vecchi E
Int J Immunopathol Pharmacol; 2011; 24(4):1027-35. PubMed ID: 22230408
[TBL] [Abstract][Full Text] [Related]
16. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Wenzler S; Schmidt-Eisenlohr E; Daschner F
Chemotherapy; 2004 Apr; 50(1):40-2. PubMed ID: 15084805
[TBL] [Abstract][Full Text] [Related]
18. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
Asbell PA; Colby KA; Deng S; McDonnell P; Meisler DM; Raizman MB; Sheppard JD; Sahm DF
Am J Ophthalmol; 2008 Jun; 145(6):951-958. PubMed ID: 18374299
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
Lister PD
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
[TBL] [Abstract][Full Text] [Related]
20. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
